- Continued progress on 5x25 strategy to advance five AAV
Therapeutics from our internal pipeline and licensed programs into
pivotal-stage or commercial products by 2025
- RGX-314 program for the treatment of wet AMD and diabetic
retinopathy, being developed in collaboration with AbbVie, remains
on track for first BLA filing in 2024
-
- Enrollment ongoing in the pivotal ATMOSPHERE® and
ASCENT™ clinical trials of RGX-314 for the treatment of wet AMD
using subretinal delivery
- Presented positive interim data from RGX-314 trials for the
treatment of wet AMD - the Phase II AAVIATE® trial using
suprachoroidal delivery and the Phase I/IIa Long-term Follow-up
study using subretinal delivery
-
- Announced expansion of AAVIATE trial to include Cohort 6 at
third dose level with short-course prophylactic ocular steroids
following RGX-314 administration
- Presented additional positive interim data from Phase II
ALTITUDE® trial of RGX-314 for the treatment of diabetic
retinopathy using suprachoroidal delivery
-
- Announced dose escalation and expansion of ALTITUDE trial to
include Cohorts 4 and 5 at new, third dose level with short-course
prophylactic ocular steroids following RGX-314
administration
- AFFINITY DUCHENNE™ Phase I/II trial of RGX-202 remains on
track for dosing in the first half of 2023
- CAMPSIITE™ pivotal program of RGX-121 is active and
enrolling patients for the treatment of MPS II; remains on track to
file a BLA in 2024 using the accelerated approval pathway
- $617 million in cash, cash
equivalents and marketable securities of as of September 30, 2022; operational runway into
2025
- Conference call Thursday, November
3rd at 8:30 a.m.
ET
ROCKVILLE, Md., Nov. 3, 2022
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced
financial results for the third quarter ended September 30, 2022, and recent operational
highlights.
"REGENXBIO has seen continued progress since our last earnings
update, with encouraging data updates across four of our key gene
therapy programs that make up our '5x'25' strategy," said
Kenneth T. Mills, President and
Chief Executive Officer of REGENXBIO. "We shared multiple updates
for our lead program, RGX-314, that is being developed in
collaboration with AbbVie, including new long-term follow-up data
for RGX-314 subretinal delivery that supports our anticipated 2024
BLA filing. We also shared new Phase II data for RGX-314
suprachoroidal delivery in both wet AMD and diabetic retinopathy.
We are expanding these trials in both indications as we continue
developing this novel approach to delivering gene therapy with the
potential to expand patient access to the in-office setting. Within
our rare disease pipeline, we also announced new data for RGX-121,
our gene therapy for the treatment of MPS II, and we continue
enrolling in the pivotal CAMPSIITE trial that we expect to support
a planned BLA filing in 2024 using the accelerated approval
pathway. We remain well funded to execute upon our goals and look
forward to keeping you updated on the advancement of our programs
as we finish the year and look ahead to 2023."
Program Highlights and Milestones
RGX-314: RGX-314 is an investigational one-time AAV
Therapeutic being developed in collaboration with AbbVie for the
treatment of wet age-related macular degeneration (wet AMD),
diabetic retinopathy (DR) and other additional chronic retinal
conditions. RGX-314 uses the NAV® AAV8 vector to deliver
a gene encoding a therapeutic antibody fragment to inhibit vascular
endothelial growth factor (VEGF).
- RGX-314 Subretinal Delivery for the Treatment of Wet AMD
-
- Enrollment is ongoing in ATMOSPHERE® and ASCENT™,
two pivotal clinical trials to evaluate the efficacy and safety of
RGX-314 in patients with wet AMD using the subretinal delivery
approach. The ASCENT trial is the first trial to be initiated by
REGENXBIO under the eye care collaboration with AbbVie.
- Pivotal trials are expected to support Biologics License
Application (BLA) submission for RGX-314 in 2024.
- In October 2022, REGENXBIO
announced data from the Phase I/IIa Long-term Follow-up study of
RGX-314 for the treatment of wet AMD using subretinal delivery at
the American Academy of Ophthalmology (AAO) Annual Meeting.
-
- As of August 29, 2022, RGX-314
continued to be generally well-tolerated in the long-term follow-up
study (n=37).
- Patients treated with RGX-314 continued to demonstrate a
long-term, durable treatment effect in Cohort 3 up to four years
and in Cohort 4 up to three years. Stable to improved visual acuity
was observed, with a mean best corrected visual acuity (BCVA) of
+12 letters from baseline at four years for Cohort 3 patients and
-5 letters from baseline at three years for Cohort 4 patients
following RGX-314 administration.
- RGX-314 Suprachoroidal Delivery for the Treatment of Wet
AMD
-
- In October 2022, REGENXBIO
announced new data from the Phase II AAVIATE® trial of
RGX-314 for the treatment of wet AMD using suprachoroidal
delivery.
-
- As of August 1, 2022, RGX-314
suprachoroidal delivery was reported to be well tolerated across 85
patients dosed in Cohorts 1-5. Mild intraocular inflammation was
reported at similar incidence in the first and second dose levels,
with an increase in incidence in mild to moderate inflammation seen
at the third dose level (Cohort 4). All intraocular inflammation
resolved with topical corticosteroids.
- Patients treated in the RGX-314 arms and the ranibizumab
control arm both continued to demonstrate stable BCVA and central
retina thickness (CRT) at 6 months. In addition, a meaningful
reduction in anti-VEGF treatment burden following administration of
RGX-314 was observed and ranged from -64% to -85% across all
cohorts. The highest reduction in treatment burden was observed in
the third dose level, with patients receiving a mean of 1.3
injections over six months following administration of RGX-314,
which represents an 85% reduction in anti-VEGF treatment
burden.
- Ten out of 15 patients (67%) in the third dose level received
no anti-VEGF injections over six months following RGX-314
administration.
- Interim data from the second dose level (Cohorts 2 and 3)
suggested there was no meaningful difference in safety and vision
outcomes for patients who are neutralizing antibody (NAb)
positive.
- The AAVIATE trial has expanded to include a new cohort at the
third dose level with short-course prophylactic ocular steroids
following RGX-314 administration to evaluate the ability to prevent
or reduce the occurrence of the mild to moderate intraocular
inflammation seen in previous cohorts. Patients will be enrolled in
Cohort 6 regardless of NAb status.
- RGX-314 Suprachoroidal Delivery for the Treatment of DR
-
- The Phase II ALTITUDE® trial has expanded to include
a higher third dose level (1x1012 GC/eye), with patients
stratified by Early Treatment Diabetic Retinopathy Study-Diabetic
Retinopathy Severity Scale (DRSS) levels across cohorts and all
receiving short-course prophylactic ocular steroids following
RGX-314 administration.
- As of October 17, 2022, RGX-314
was reported to be well tolerated across 50 patients dosed in
Cohorts 1-3 at two dose levels (D1 and D2). Three patients had
intraocular inflammation, all of which were mild and resolved on
topical corticosteroids.
- No meaningful differences in safety outcomes were observed at
six months for patients who are NAb positive.
- BCVA remained stable in Cohorts 1-3 through six months.
- Patients treated with RGX-314 in Cohorts 1-3 demonstrated
clinically meaningful improvements in disease severity and less
disease worsening versus observation control at six months as
measured by DRSS. Specifically:
-
- 20% (D1: 40%, D2: 11%) achieved ≥2-step DRSS improvement vs.
10% in control
- 54% (D1: 60%, D2: 51%) achieved any DRSS improvement vs. 20% in
control
- 0% (D1: 0%, D2: 0%) worsened ≥2 steps vs. 20% in control
RGX-202: RGX-202 is an investigational one-time AAV
Therapeutic for the treatment of Duchenne Muscular Dystrophy
(Duchenne), using the NAV AAV8 vector to deliver a transgene for a
novel microdystrophin that includes the functional elements of the
C-Terminal (CT) domain as well as a muscle specific promoter to
support a targeted therapy for improved resistance to muscle damage
associated with Duchenne.
- Preparation for the initiation of the AFFINITY DUCHENNE™ Phase
I/II trial continues, including readying clinical trial sites and
manufacturing additional clinical supply for the trial.
- REGENXBIO anticipates dosing the first patient in this trial in
the first half of 2023.
RGX-121: RGX-121 is an investigational one-time AAV
Therapeutic for the treatment of Mucopolysaccharidosis Type II (MPS
II), also known as Hunter Syndrome, using the NAV AAV9 vector to
deliver the gene that encodes the iduronate-2-sulfatase (I2S)
enzyme.
- CAMPSIITE™, a multicenter, open-label, Phase I/II/III trial for
the treatment of patients up to 5 years old diagnosed with MPS II,
is active and enrolling patients. The trial is expected to enroll
up to 10 MPS II patients using commercial-scale cGMP material to
support a BLA filing in 2024 using the accelerated approval
pathway, with the potential to enroll additional patients.
- In August 2022, REGENXBIO
announced positive interim data from the CAMPSIITE trial of
RGX-121
-
- As of August 1, 2022, RGX-121 was
reported to be well-tolerated across all cohorts in 14 patients
dosed with RGX-121.
- Patients in all three cohorts demonstrated encouraging,
dose-dependent reductions of cerebrospinal fluid (CSF)
glycosaminoglycans (GAGs), key biomarkers of I2S enzyme activity,
following one-time administration of RGX-121.
- Improvements in neurodevelopmental function and caregiver
reported outcomes in Cohorts 1 and 2 demonstrated CNS activity up
to 2 years after RGX-121 administration.
- GAGs in the CSF have the potential to be considered a surrogate
biomarker that is reasonably likely to predict clinical benefit in
MPS II disease under the accelerated approval pathway, as buildup
of GAGs in the CSF of MPS II patients correlates with clinical
manifestations, including neurodevelopmental deficits.
- The Phase I/II trial of RGX-121 for the treatment of pediatric
patients with MPS II over the age of five years old is also
ongoing.
RGX-111: RGX-111 is an investigational one-time AAV
Therapeutic for the treatment of severe Mucopolysaccharidosis Type
I (MPS I), using the NAV AAV9 vector to deliver the α-l-iduronidase
(IDUA) gene.
- REGENXBIO continues with plans to enroll additional patients in
a Cohort 2 expansion arm of the Phase I/II trial.
Operational Updates
- The REGENXBIO Manufacturing Innovation Center is fully
operational, producing GMP bulk substance lots to support programs
using the NAVXpress™ process platform.
-
- State-of-the-art cGMP gene therapy manufacturing facility is
designed to meet global clinical and commercial regulatory
standards and enable the Company to efficiently advance its
AAV-based gene therapy pipeline from research and early development
to clinical programs to commercial readiness.
- REGENXBIO is one of only a few gene therapy companies worldwide
with a GMP facility capable of production at scales up to 2,000
liters.
NAV Technology Licensee Program Highlights
As of September 30, 2022,
REGENXBIO's NAV Technology Platform was being applied in one
marketed product and multiple clinical stage partnered programs,
with the potential to impact a broad range of therapeutic areas and
disease indications.
- Zolgensma®, a one-time AAV Therapeutic for the
treatment of spinal muscular atrophy (SMA), is a marketed product
utilizing REGENXBIO's NAV AAV9 vector. In October 2022, Novartis AG reported third quarter
global sales of Zolgensma of $319
million (>2,500 patients treated worldwide).
- In September 2022, Rocket
Pharmaceuticals, Inc. announced positive updates from the Phase 1
clinical trial for RP-A501 in Danon Disease. Pediatric efficacy
data showed initial improvements across clinical, functional and
biomarker endpoints with six to nine months of follow-up; positive
results including protein expression obtained at three and six
months were consistent with adult cohorts at similar timeframe. The
clinical data presented to date is expected to support a Phase 2
pivotal study. RP-A501 is being developed as a one-time gene
therapy utilizing REGENXBIO's NAV AAV9 vector.
- In August 2022, uniQure N.V.
announced the initiation of an IND-enabling GLP toxicology study in
non-human primates to support an IND submission for AMT-260 in
rTLE. AMT-260 is being developed as a one-time gene therapy
utilizing REGENXBIO's NAV AAV9 vector.
- In July 2022, Ultragenyx
Pharmaceutical Inc. announced that dosing and enrollment of the
Phase 3 study of DTX401 for Glycogen Storage Disease Type Ia
(GSDIa) is ongoing, it expects to initiate the Phase 3 study of
DTX301 for Ornithine Transcarbamylase (OTC) Deficiency in the
second half of 2022, and it is dosing patients in the first stage
of the Cyprus2+ study of UX701 for Wilson Disease. DTX401 and
DTX301 are both being developed as one-time gene therapies
utilizing REGENXBIO's NAV AAV8 vector and UX701 is being developed
as a one-time gene therapy utilizing REGENXBIO's NAV AAV9
vector.
Financial Results
Cash Position: Cash, cash equivalents and marketable
securities were $617.0 million as of
September 30, 2022, compared to
$849.3 million as of December 31, 2021. The decrease was primarily
driven by cash used to fund operating activities and capital
expenditures and temporary unrealized losses on marketable debt
securities during the nine months ended September 30, 2022.
Revenues: Revenues were $26.5
million for the three months ended September 30, 2022, compared to $30.8 million for the three months ended
September 30, 2021. The decrease was
primarily attributable to Zolgensma royalty revenues, which
decreased from $30.3 million for the
third quarter of 2021 to $25.2
million for the third quarter of 2022. Zolgensma royalty
revenues for the nine months ended September
30, 2022 were $75.1 million
for the nine months ended September 30,
2022, compared to $66.9
million for the nine months ended September 30, 2021.
Research and Development Expenses: Research and
development expenses were $63.3
million for the three months ended September 30, 2022, compared to $47.9 million for the three months ended
September 30, 2021. The increase was
primarily attributable to personnel costs as a result of increased
headcount, and costs associated with clinical trials and
manufacturing-related activities for our lead product
candidates.
General and Administrative Expenses: General and
administrative expenses were $20.9
million for the three months ended September 30, 2022, compared to $21.0 million for the three months ended
September 30, 2021.
Net Loss: Net loss was $75.5
million, or $1.75 basic and
diluted net loss per share, for the three months ended September 30, 2022, compared to a net loss of
$58.4 million, or $1.37 basic and diluted net loss per share, for
the three months ended September 30,
2021.
Financial Guidance
Based on its current operating plan, REGENXBIO expects its
balance in cash, cash equivalents and marketable securities of
$617.0 million as of September 30, 2022 to fund its operations into
2025.
Conference Call
In connection with this announcement, REGENXBIO will host a
conference call and webcast today at 8:30
a.m. ET. Listeners can register for the webcast via this
link. Analysts wishing to participate in the question and answer
session should use this link. A replay of the webcast will be
available via the company's investor website approximately two
hours after the call's conclusion. Those who plan on participating
are advised to join 15 minutes prior to the start time.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates,
including late-stage and commercial programs, in multiple
therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to
progress five AAV Therapeutics from our internal pipeline and
licensed programs into pivotal-stage or commercial products by
2025.
Forward-Looking Statements
This press release includes "forward-looking statements," within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements express a belief, expectation or
intention and are generally accompanied by words that convey
projected future events or outcomes such as "believe," "may,"
"will," "estimate," "continue," "anticipate," "assume," "design,"
"intend," "expect," "could," "plan," "potential," "predict,"
"seek," "should," "would" or by variations of such words or by
similar expressions. The forward-looking statements include
statements relating to, among other things, REGENXBIO's future
operations, clinical trials, costs and cash flow. REGENXBIO has
based these forward-looking statements on its current expectations
and assumptions and analyses made by REGENXBIO in light of its
experience and its perception of historical trends, current
conditions and expected future developments, as well as other
factors REGENXBIO believes are appropriate under the circumstances.
However, whether actual results and developments will conform with
REGENXBIO's expectations and predictions is subject to a number of
risks and uncertainties, including the timing of enrollment,
commencement and completion and the success of clinical trials
conducted by REGENXBIO, its licensees and its partners, the timing
of commencement and completion and the success of preclinical
studies conducted by REGENXBIO and its development partners, the
timely development and launch of new products, the ability to
obtain and maintain regulatory approval of product candidates, the
ability to obtain and maintain intellectual property protection for
product candidates and technology, trends and challenges in the
business and markets in which REGENXBIO operates, the size and
growth of potential markets for product candidates and the ability
to serve those markets, the rate and degree of acceptance of
product candidates, the impact of the COVID-19 pandemic or similar
public health crises on REGENXBIO's business, and other factors,
many of which are beyond the control of REGENXBIO. Refer to the
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of
REGENXBIO's Annual Report on Form 10-K for the year ended
December 31, 2021, and comparable
"risk factors" sections of REGENXBIO's Quarterly Reports on Form
10-Q and other filings, which have been filed with the U.S.
Securities and Exchange Commission (SEC) and are available on the
SEC's website at www.sec.gov. All of the forward-looking statements
made in this press release are expressly qualified by the
cautionary statements contained or referred to herein. The actual
results or developments anticipated may not be realized or, even if
substantially realized, they may not have the expected consequences
to or effects on REGENXBIO or its businesses or operations. Such
statements are not guarantees of future performance and actual
results or developments may differ materially from those projected
in the forward-looking statements. Readers are cautioned not to
rely too heavily on the forward-looking statements contained in
this press release. These forward-looking statements speak only as
of the date of this press release. Except as required by law,
REGENXBIO does not undertake any obligation, and specifically
declines any obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
REGENXBIO INC.
|
CONSOLIDATED BALANCE
SHEETS
|
(unaudited)
|
(in
thousands)
|
|
|
|
September 30,
2022
|
|
|
December 31,
2021
|
|
Assets
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
118,544
|
|
|
$
|
345,209
|
|
Marketable
securities
|
|
|
263,874
|
|
|
|
112,230
|
|
Accounts receivable,
net
|
|
|
32,549
|
|
|
|
32,439
|
|
Prepaid
expenses
|
|
|
14,824
|
|
|
|
18,752
|
|
Other current
assets
|
|
|
6,848
|
|
|
|
10,196
|
|
Total current
assets
|
|
|
436,639
|
|
|
|
518,826
|
|
Marketable
securities
|
|
|
234,594
|
|
|
|
391,907
|
|
Accounts receivable,
net
|
|
|
1,803
|
|
|
|
2,262
|
|
Property and equipment,
net
|
|
|
140,906
|
|
|
|
131,547
|
|
Operating lease
right-of-use assets
|
|
|
59,471
|
|
|
|
60,904
|
|
Restricted
cash
|
|
|
2,030
|
|
|
|
2,030
|
|
Other assets
|
|
|
8,350
|
|
|
|
6,428
|
|
Total
assets
|
|
$
|
883,793
|
|
|
$
|
1,113,904
|
|
Liabilities and
Stockholders' Equity
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
25,210
|
|
|
$
|
11,387
|
|
Accrued expenses and
other current liabilities
|
|
|
44,462
|
|
|
|
76,111
|
|
Deferred
revenue
|
|
|
5,903
|
|
|
|
3,333
|
|
Operating lease
liabilities
|
|
|
3,608
|
|
|
|
1,752
|
|
Liability related to
sale of future royalties
|
|
|
44,365
|
|
|
|
37,889
|
|
Total current
liabilities
|
|
|
123,548
|
|
|
|
130,472
|
|
Operating lease
liabilities
|
|
|
84,673
|
|
|
|
84,929
|
|
Liability related to
sale of future royalties
|
|
|
103,084
|
|
|
|
133,460
|
|
Other
liabilities
|
|
|
8,664
|
|
|
|
745
|
|
Total
liabilities
|
|
|
319,969
|
|
|
|
349,606
|
|
Stockholders'
equity
|
|
|
|
|
|
|
Preferred stock; no
shares issued and outstanding
at September 30, 2022 and December 31, 2021
|
|
|
—
|
|
|
|
—
|
|
Common stock; 43,292
and 42,831 shares issued
and outstanding at September 30, 2022 and
December 31, 2021, respectively
|
|
|
4
|
|
|
|
4
|
|
Additional paid-in
capital
|
|
|
963,694
|
|
|
|
928,095
|
|
Accumulated other
comprehensive loss
|
|
|
(18,256)
|
|
|
|
(2,569)
|
|
Accumulated
deficit
|
|
|
(381,618)
|
|
|
|
(161,232)
|
|
Total stockholders'
equity
|
|
|
563,824
|
|
|
|
764,298
|
|
Total liabilities and
stockholders' equity
|
|
$
|
883,793
|
|
|
$
|
1,113,904
|
|
REGENXBIO INC.
|
CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
|
(unaudited)
|
(in thousands,
except per share data)
|
|
|
|
Three
Months
|
|
|
Nine
Months
|
|
|
|
Ended September
30,
|
|
|
Ended September
30,
|
|
|
|
2022
|
|
|
2021
|
|
|
2022
|
|
|
2021
|
|
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
License and royalty
revenue
|
|
$
|
26,512
|
|
|
$
|
30,773
|
|
|
$
|
81,379
|
|
|
$
|
71,692
|
|
Total
revenues
|
|
|
26,512
|
|
|
|
30,773
|
|
|
|
81,379
|
|
|
|
71,692
|
|
Operating
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of
revenues
|
|
|
13,094
|
|
|
|
14,105
|
|
|
|
41,762
|
|
|
|
28,775
|
|
Research and
development
|
|
|
63,313
|
|
|
|
47,855
|
|
|
|
179,948
|
|
|
|
133,459
|
|
General and
administrative
|
|
|
20,921
|
|
|
|
21,030
|
|
|
|
64,071
|
|
|
|
57,293
|
|
Credit losses and
other
|
|
|
229
|
|
|
|
5,131
|
|
|
|
703
|
|
|
|
5,781
|
|
Total operating
expenses
|
|
|
97,557
|
|
|
|
88,121
|
|
|
|
286,484
|
|
|
|
225,308
|
|
Loss from
operations
|
|
|
(71,045)
|
|
|
|
(57,348)
|
|
|
|
(205,105)
|
|
|
|
(153,616)
|
|
Other Income
(Expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income from
licensing
|
|
|
18
|
|
|
|
117
|
|
|
|
265
|
|
|
|
700
|
|
Investment
income
|
|
|
1,497
|
|
|
|
5,535
|
|
|
|
3,357
|
|
|
|
6,514
|
|
Interest
expense
|
|
|
(5,954)
|
|
|
|
(6,709)
|
|
|
|
(18,944)
|
|
|
|
(19,777)
|
|
Total other income
(expense)
|
|
|
(4,439)
|
|
|
|
(1,057)
|
|
|
|
(15,322)
|
|
|
|
(12,563)
|
|
Loss before income
taxes
|
|
|
(75,484)
|
|
|
|
(58,405)
|
|
|
|
(220,427)
|
|
|
|
(166,179)
|
|
Income Tax Benefit
(Expense)
|
|
|
—
|
|
|
|
—
|
|
|
|
41
|
|
|
|
(4)
|
|
Net loss
|
|
$
|
(75,484)
|
|
|
$
|
(58,405)
|
|
|
$
|
(220,386)
|
|
|
$
|
(166,183)
|
|
Other Comprehensive
Loss
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized loss on
available-for-sale securities, net
|
|
|
(3,493)
|
|
|
|
(30)
|
|
|
|
(15,687)
|
|
|
|
(925)
|
|
Total other
comprehensive loss
|
|
|
(3,493)
|
|
|
|
(30)
|
|
|
|
(15,687)
|
|
|
|
(925)
|
|
Comprehensive
loss
|
|
$
|
(78,977)
|
|
|
$
|
(58,435)
|
|
|
$
|
(236,073)
|
|
|
$
|
(167,108)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share,
basic and diluted
|
|
$
|
(1.75)
|
|
|
$
|
(1.37)
|
|
|
$
|
(5.11)
|
|
|
$
|
(3.93)
|
|
Weighted-average common
shares outstanding, basic and diluted
|
|
|
43,251
|
|
|
|
42,629
|
|
|
|
43,103
|
|
|
|
42,324
|
|
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
Chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-reports-third-quarter-2022-financial-results-and-recent-operational-highlights-301667151.html
SOURCE REGENXBIO Inc.